Close

TAKEDA

In 2008, Domain Therapeutics signed a research agreement with Takeda Pharmaceutical Company Limited (Tokyo, Japan)

Under the agreement, Domain Therapeutics applied its DTect-All™ platform to identify novel drug candidates that target undisclosed G Protein-Coupled Receptors (GPCRs) of interest to Takeda. In 2009 Domain Therapeutics announced that it has successfully completed the first milestone in this research agreement with Takeda Pharmaceutical. Following milestone completion have not been publicly announced.